Congressman Helps Raise Money to Legalize Psilocybin Mushroom Therapy

The representative for Oregon’s 3rd Congressional district Earl Francis Blumenauer, who is a chief advocate for cannabis reform, formally announced his support of Oregon’s initiative to legalize psilocybin mushrooms to be used for therapeutic purposes. He is also helping to raise money for the company.

He stated in a mass email that he fully supported the measure as it addresses mental health which is key issue in the community, in a responsible and innovative way. Additionally, he stated that the legalization of psilocybin therapy was an important tool that deserved everyone’s support.

The measure in question, Measure 109, provides residents of Oregon who live with anxiety and depression a chance to deal with their mental health issues in a program that is designed for support and safety. He added that this healthcare policy would help thousands.

Measure 109 offers hope with the advanced treatment option of psilocybin therapy. Research from top universities in America shows that psilocybin therapy may assist people who suffer from anxiety, addiction and depression. Measure 109 was developed by both mental health and therapeutic experts and brings forth this treatment option through a licensed and research-based system which protects and supports those in need of assistance.

Studies have shown that psilocybin therapy helps people with terminal diagnoses who suffer from anxiety and end-of-life depression come to terms with their diagnoses. This is therefore an opportunity to improve end-of-life care.

The first time Rep. Blumenauer showed his psilocybin initiative support was in January. This is a remarkable endorsement especially if you consider that very few congressional legislators support psychedelics reform, in spite of the expanding localized movement that is calling for the decriminalization of entheogenic substances in various cities in the country.

The representative for Massachusetts’s 4th Congressional district Joseph Patrick Kennedy III who supports legalization but was formerly against marijuana reform recently stated that there was potential in psychedelics therapeutic benefits.

Rep. Blumenauer also added that the Measure 109 can win in the November ballot but to do so, it requires resources in order to educate voters on the benefits as well as its protections, hence the need for a campaign to raise funds.

In addition to this, an initiative to decriminalize psychedelics has formally qualified for the November vote in Washington, D.C.

For the moment, voters in Oregon will also have the measure to fund treatment services and decriminalize drug possession on their November ballots.

Countries like Canada are more open minded to certain policy changes of the same with the health minister granting exceptions to 4 cancer patients, thus allowing them to utilize psilocybin mushrooms for their end-of-life care.

Additionally, the Canadian government has to formally respond to a petition that called for the psychedelics decriminalization after it collected about 15,000 signatures.

Allis looking up for the psychedelic industry, and this could explain why sector actors like Cybin Corp. are investing heavily in psychedelic R&D.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.